Is Syncom Formul. overvalued or undervalued?

As of 14 November 2025, the valuation grade for Syncom Formul. has moved from very expensive to expensive. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 24.77, an EV to EBITDA of 21.23, and a PEG ratio of 0.28, which indicates potential growth relative to its price.
In comparison to peers, Syncom Formul.'s PE ratio is significantly lower than Sun Pharma's 36.49 and Divi's Lab's 69.65, both categorized as expensive and very expensive, respectively. However, it is higher than Cipla's attractive PE of 22.72, suggesting that while Syncom Formul. is overvalued, it remains competitive within the industry. The recent stock performance shows a 3.30% return over the past week, outperforming the Sensex's 1.62%, but the year-to-date return of -17.00% highlights ongoing challenges.